GSK declines to exercise cancer vaccine licence option
GlaxoSmithKline (GSK) has decided not to exercise a previously granted right to negotiate a licence agreement with Danish company Pharmexa for its HER-2 Protein AutoVac vaccine, which recently started Phase II trials in breast cancer.
GlaxoSmithKline (GSK) has decided not to exercise a previously granted right to negotiate a licence agreement with Danish company Pharmexa for its HER-2 Protein AutoVac vaccine, which recently started Phase II trials in breast cancer.
Pharmexa's strategy for the vaccine is to develop the product through phase II before a development and marketing partner is sought.
Pharmexa ceo Jakob Schmidt said: 'Now was not the right time for having these discussions, and I fully agree with their decision. I still expect GSK to be one of a handful of potential partners we will talk to when we have proof of concept data from the Phase II programme in the second half of 2006.'